628731-60-2

Upstream product

• 62141-26-8 ethyl 1,4-dioxaspiro[4.5]dec-8-ylacetate 
• 51656-91-8 ethyl 1,4-dioxaspiro[4,5]dec-8-ylideneacetate 
• 135761-76-1 2-(1,4-dioxaspiro[4.5]decan-8-yl)ethanol 
• 100-39-0 benzyl bromide 
• 32863-01-7 4-(2-hydroxyethyl)cyclohexan-1-one 
• 90199-14-7 2-(4-Keto-cyclohexen-⁽¹⁾-yl)-ethylalkohol 
• 67175-80-8 1-methoxy-4-(2-hydroxyethyl)-cyclohexa-1,4-diene 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 628731-59-9 8-(2-(benzyloxy)ethyl)-1,4-dioxaspiro[4.5]decane 

Downstream Products

• 943551-49-3 [2-(4,4-diethoxycyclohexyl)ethoxymethyl]benzene 
• 1613270-16-8 (trans-4-(2-(benzyloxy)ethyl)cyclohexyl)methanol 
• 1613270-17-9 trans-4-(2-(benzyloxy)ethyl)cyclohexanecarbaldehyde 
• 1613270-18-0 (R,E)-N-((trans-4-(2-(benzyloxy)ethyl)cyclohexyl)methylene)-2-methylpropane-2-sulfinamide 
• 1613270-19-1 (R)-N-(1-(trans-4-(2-(benzyloxy)ethyl)cyclohexyl)but-3-enyl)-2-methylpropane-2-sulfinamide 
• 1613270-20-4 tert-butyl-N-(1-(trans-4-(2-(benzyloxy)ethyl)cyclohexyl)but-3-enyl)-carbamate 
• 1613270-21-5 C₁₉H₂₉NO 
• 1613270-22-6 tert-butyl-N-(1-(trans-4-(2-(benzyloxy)ethyl)cyclohexyl)-3-oxopropyl)carbamate 
• 1613270-23-7 tert-butyl 1-(trans-4-(2-hydroxyethyl)cyclohexyl)-3-oxopropylcarbamate 
• 1613270-24-8 2-(trans-4-(1-(tert-butoxycarbonylamino)-3-oxopropyl)cyclohexyl)ethyl acetate 
• 1613270-25-9 2-(trans-4-(1-(tert-butoxycarbonylamino)-3-hydroxypropyl)cyclohexyl)ethyl acetate 
• 1613270-26-0 2-(trans-4-(3-azido-1-(tert-butoxycarbonylamino)propyl)cyclohexyl)ethyl acetate 
• 1635424-86-0 C₁₉H₃₅NO₇S 
• 1613270-27-1 2-(trans-4-(3-amino-1-(tert-butoxycarbonylamino)propyl)cyclohexyl)ethyl acetate 

Relevant academic research and scientific papers

SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS

Substituted cyclohexyl chemical entities of Formula (I): wherein Ra, G, and Rb have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of meth

Development of an efficient route toward meiogynin A-inspired dual inhibitors of Bcl-xL and Mcl-1 anti-apoptotic proteins

The synthesis, on a large scale, with very good yield and er via an efficient strategy, of a chiral 4-substituted 2-cyclohexenone intermediate, was a milestone in the synthesis of seven analogues of meiogynin A, a natural sesquiterpenoid dimer. These comp

BETA-LACTAMASE INHIBITORS

Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.

Alpha-2adrenergic agonists

A compound is disclosed herein comprising or a pharmaceutically acceptable salt or a prodrug thereof; wherein R is OH or NH2. Methods, compositions, and medicaments related thereto are also disclosed.

PYRIDINYL AMINE DERIVATIVES AS INHIBITORS OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP)

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the variables are as defined, useful as inhibitors of chlosteryl ester transfer protein.

BICYCLIC DERIVATIVES AS CETP INHIBITORS

The present invention relates to novel compounds of formula (I): or a pharmaceutical composition thereof, with all the variables being defined in the text. The present invention further relates to the use of the compounds herein for treatment of or delay

Novel methods for identifying improved, non-sedating alpha-2 agonists

The present invention provides methods of preventing or alleviating sympathetically-enhanced conditions, neurological conditions, ocular conditions and chronic pain without concomitant sedation by peripherally administering to a subject an effective amoun

Nonsedating alpha-2 agonists

The present invention provides an α-2A/α-1A selective agonist that includes a compound represented by Structure 1 or a pharmaceutically acceptable salt, ester, amide, sterioisomer or racemic mixture thereof. The present invention further provides a pharma

THERAPEUTIC AMIDE DERIVATIVES

The present invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein: A and B independently represent CH2 or O, with the proviso that A and B are not simultaneously O; Cy represents one of the following Formula (II) optionally substituted by one to three groups selected from hydroxy, halogen, C1-6alkyl, C1-6alkoxy, C1-6 haloalkyl, C1-6alkylamino and amino; R1 and R2 are independently selected from hydroxy, halogen, C1-6alkyl, C1-6alkoxy, C1-6 haloalkyl and C3-8 cycloalkyl; n represents an integer from 0-4; X is hydrogen, hydroxy, halogen or C1-6alkoxy; Y is oxy, thio, a 1-4 membered alkylene, a 2-4 membered alkylene ether, 2-4 membered alkylene thioether or an oxyethyleneoxy group, optionally substituted by 1 to 4 groups independently selected from hydroxy, halogen, C1-6alkyl, C1-6alkoxy and C1-6 haloalkyl; Z is CH or N; and p represents an integer from 0-5 when Z is CH or 0-4 when Z is N; when p represents 2 or more, two of R2s may be taken together with the carbon atoms to which they are attached to form a 5-8 membered cycloalkyl ring to processes for the preparation of, intermediates used in the preparation of, compositions containing such compounds and the uses of such compounds as antagonists of the NMDA NR2B receptor.

4-(2-Methyl-5,6,7,8-tetrahydro-quinolin-7-ylmethyl)-1,3-dihydro-imidazole-2-thione as specific alpha2B agonist and methods of using the same

The compound of the formula wherein the * indicates an asymmetric carbon, is specific to alpha2B adrenergic receptors in preference over alpha2A and alpha2C adrenergic receptors, and as such has no or only minimal cardivascular and/or sedatory activity. The compound is useful as medicament in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors.